Chimerix's CMX157 Shows Potential To Treat Multi-Drug-Resistant HIV And Improve The Activity And Toxicity Profile Of Tenofovir
Source: Medical News Today
Thursday 29th July, 2010
Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl ... ...
Read the full story at
Medical News Today
Email this story to a friend
Have your say on this story
